Amgen Inc. Collaboration Agreements
16 Contracts & Agreements
- Second Amendment to Collaboration Agreement, entered into as of February 26, 2023, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd (Filed With SEC on April 28, 2023)
- First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd (Filed With SEC on August 5, 2022)
- Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 16, 2022)
- Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been... (Filed With SEC on January 31, 2022)
- Amended and Restated Collaboration Agreement, dated June 2, 2021, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on August 4, 2021)
- Amendment No. 7 to the Collaboration Agreement, dated December 18, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 9, 2021)
- Amendment No. 2 to the Collaboration Agreement, dated August 19, 2020, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on October 29, 2020)
- Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016,... (Filed With SEC on July 29, 2020)
- Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC (Filed With SEC on May 1, 2020)
- Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd (Filed With SEC on February 12, 2020)
- Amendment No. 1 to the Collaboration Agreement, dated March 20, 2018, by and between Novartis Pharma AG and Amgen Inc. (portions of the exhibit have been omitted pursuant to a... (Filed With SEC on April 25, 2018)
- Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)
- Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)
- Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)
- Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on July 26, 2017)
- Collaboration Agreement By and Between Amgen Inc. and Daiichi Sankyo Company, Limited (Filed With SEC on November 9, 2007)
